A novel brain-selective acetylcholinesterase inhibitor, SDZ ENA 713, is under development for the treatment of dementia of the Alzheimer type. To determine the threshold dose for central activity, single doses of the rompound were administered to 20 young male lI01unteers in a double-blind cross-over design and the effec ts on the sleep electroencephalography studied. The first group of eight volunteers received in random order: placebo, 0.5 mg; and 1 mg SDZ ENA 713. The second group of 12 volunteers received: placebo, 1.3 mg; and 2 KEYWORDS: SDZ ENA 713; Acetylcholinesterase inhibitor; Dementia; Sleep
The drug SDZ ENA 713 is an acetylcholinesterase (AChE) inhibitor being developed for the symptomatic treatment of dementia of the Alzheimer type. In ani ma! studies SDZ ENA 713 shows a selectivity for brain AChE compared with that in the periphery. Further more, at a given dose AChE inhibition is more pro nounced in the rat cortex and hippocampus than in the corpus striatum and brain stem. The drug SDZ ENA 713 synchronizes hippocampal theta waves in the rat electroencephalogram (EEG) that reflect an increase of muscarini c activity in the hippocampus (Enz et al. 1989 ).
mg SDZ ENA 713. Sleep quality was not affected by the study medication, which was well tolerated by all subjects. A statistically significant increase in rapid-eye movement sleep density was observed after doses of 1 mg, 1.3 mg, and 2 mg. Rapid-eye movement latency and slow-wave sleep were not altered. The results demonstrate that SDZ ENA 713 is centrally active in man at well-tolerated doses. [Neuropsychopharmacology 8:87-92, 1993J A number of polygraphic sleep studies have shown that cholinergic agents facilitate rapid-eye movement (REM) sleep in man (shiromani et al. 1987) , possibly via M2 receptors (Velazquez-Moctezuma et al. 1989) . The classic AChE inhibitor physostigmine and other cholinomimetic substances have been studied in this regard. Intravenous administration of physostigmine accelerated the onset of the nrst REM phase (sitaram et al. 1976) . A similar shortening of REM latency in healthy volunteers has been observed after adminis tration of the muscarinic agonists arecoline (sitaram et al. 1978) and pilocarpine (Berkowitz et al. 1990 ). Rapid eye movement density was not altered after these agents. Another experimental muscarinic agonist, Rs 86, has been shown to induce marked shortening of REM latency in normal volunteers (Spiegel 1984) . This effect was also present in patients with major depres sion, with an increase in the density of REM sleep (Lauer et al. 1989) .
The purpose of the current study was to determine whether similar effects on REM sleep could be observed in man after well-tolerated single oral doses of sDZ ENA 713 and to determine the threshold dose for such effects.
METHODS

Subjects
Twenty healthy male subjects aged 18 to 40 years were studied in two groups. After a general medical exami nation, including an electrocardiogram (ECG), labora tory tests, and a psychiatric interview, they were found to be physically and mentally healthy. They were free of drugs, including drugs of abuse and without per sonal or family history of any psychiatric illness. The volunteers gave written informed consent prior to en tering the trial and were paid for their participation. The research protocol was approved by the local ethical com mittee.
Design
All subjects spent 5 nights in the sleep laboratory. The fIrst 2 nights were adaptation nights, on which the sub jects were administered placebo under single-blind con ditions. On the subsequent 3 nights at 2200 hours each of the subjects in Group I took either a capsule of placebo, 0.5 mg SDZ ENA 713, or 1 mg SDZ ENA 713 under randomized double-blind conditions. Each of the twelve subjects in Group II took either a capsule of placebo, 1.3 mg SDZ ENA 713, or 2 mg SDZ ENA 713. A randomized balanced cross-over design was used.
Sleep
Sleep was recorded between 2300 hours and 0700 hours by means of standard procedures: horizontal elec trooculogram (EOG), submental electromyogram, EEG (C3-A2; C4-Al; C3-C4), and ECG. Respiratory move ments were also monitored, using a belt incorporat ing a transducer ("Atemaufnehmer": ZAK, Simbach, Germany).
The records were scored under blind conditions by two experienced raters according to standardized criteria (Rechtschaff en and Kales 1968). The sleep param eters were analyzed according to the dehnitions in the standard program described by Lauer (1988) . The fol lowing sleep parameters were determined. 1993-VOL. 8, NO.1 latency (time from sleep onset to the hrst occurrence of REM stage), and REM density (the ratio of 3-second miniepochs per REM period including at least one REM to the total amount of all 3-second miniepochs per REM period). In addition, we calculated the REM densities for the fIrst, second, and third thirds of the night as well as for the fIrst, second, and third sleep cycle. Finally, we computed the ratio of the REM and non-REM period duration within each sleep cycle.
For evaluation of subjective sleep quality, after each night all subjects completed a questionnaire concern ing their subjective impression of the previous night's sleep.
Safety Data
A full medical examination including ECG and labora· tory values was performed before and after the study. Vital signs were measured before and on the mornin ! after each dose of medication.
Statistical Analysis
Background and safety data were quality controlled and entered into a computerized data bank. No statistical comparisons between the two groups were made wi� regard to these data. Sleep parameters were entered into a separate computer database. Sleep parameteI! for the different treatments were compared by one-war analysis of variance for repeated measures, (2 degrees of freedom for treatment effects in each group). Table 1 shows results for the variables of sleep coJ) tinuity and sleep architecture for the whole sample comparing placebo and drug conditions. In Group I twtt subjects were excluded from analysis, one becauseoi consistently poor sleep and one because of a I-hour de lay in drug intake on 1 night.
RESULTS
Effects of SDZ ENA 713 on Sleep
REM Measures. The changes in REM measures are summarized in Table 2 . In Group I there was signifIcant increase in REM density in the second cyck of the night after the 1 mg, but not the 0.5 mg, do�
In Group II, an increase in REM density comparee with placebo was observed after both the 1.3 mg an:! 2 mg dose (Fig. 1) . The increase in REM density WI! signifIcant in the fIrst and second thirds of the nigblt No signifIcant difference between REM latencies aJt duration of REM sleep on active and placebo medica tion were observed in either group.
Sleep Continuity. A signifIcant decrease in sleep eIII Group I 7.6 ± 8.3 3.6 ± 3.8 6.5 ± 8.4 0.5 NS Group II 1.3 ± 3.6 2.1 ± 4.8 2.9 ± 4.6 0.5 NS
• Data presented are mean ± SO.
• P < O.OS. 
Safety Data
There were no signifIcant changes in safety parameters during the study. No adverse effects occurred, except for inflamm ation and edema of the skin around the elec trodes in one subject.
There was no evidence for a change in respiratory or ventricular rate after any of the doses of SDZ ENA 713 in comparison with placebo. 
DISCUSSION
The principal fInding of this study is that SDZ ENA 713
induced a dose-dependent increase in the phasic com ponent of REM sleep, REM density. The increase was by 50% in the frrst third and by 25% in the second third of the night. The threshold dose for this effect was 1 mg, with a clear effect present at doses of 1.3 mg and 2 mg. These are single doses that have been shown to be well tolerated in young and elderly human volun teers (Gray 1990 ). The effect was prolonged, persisting clearly for the frrst two-thirds of the night (Fig. 1) . The long duration of action is in keeping with previous phar macologic data in animals and man: in rat brain a sin gle dose of SDZ ENA 713 inhibits AChE for at least 6 hours (Enz et al. 1989) ; in man, a single dose of SDZ ENA 713 inhibits plasma butyrylcholinesterase for at least 10 hours (Gray 1990 ). tained with other cholinergic drugs in normal volun teers, as shown in Table 3 .
The reason for the absence of an effect of SDZ ENA 713 on REM latency in normal control subjects is not known. It may be that higher doses would have induced such a change, there is some evidence that REM den sity is a parameter generally more sensitive to drug eff ects than REM latency (Pujol et al. 1975 ; JM Gaillard, personal communication). On the other hand, physo stigmine and pilocarpine were reported to shorten REM latency, although REM density was not signiftcantly aff ected by these compounds (Table 3 ).
An increase in REM density has been reported in depressed subjects after administration of the mus carinic agonist RS 86 (Lauer et al. 1989) . A short REM latency and an increased REM density are typical fea tures of the disturbed sleep in depression. It has been shown that increased REM density is a typical altera tion of sleep found in young depressed patients, whereas shorter REM latencies only appear in depressed patients older than 40 years (Lauer et al. 1987) . These changes in REM sleep in depression have Rapid-eye movement density is suggested to be rel atively independent of other parameters of REM sleep (Aserinsky 1969 (Aserinsky , 1973 . According to the two-process model of sleep regulation, REM sleep depends on a cir cadian oscillator, process C, whereas slow-wave sleep is assumed to reflect process 5, a sleep-dependent homeostatic process (Borbely 1982 ). Alternatively it may be that SDZ ENA 713 tends to act selectively on structures controlling REM den sity rather than those affecting REM latency. Indeed, in the rat, SDZ ENA 713 has been shown to act prefer entially on the hippocampus and cortex, rather than on the brain stem. It is tempting to speculate that the selective enhancing effect on REM density might reflect this hippocampal selectivity. However, the anatomy of the structures controlling REM density are poorly un derstood; if the hippocampus were involved, efferent pathways to the brain stem would have to be impli cated, and so far, no such pathways are known.
Nevertheless, in this regard it is of interest that Petsche The ftnding of an increased REM density after the administration of SDZ ENA 713 is of more than aca demic interest. Rapid-eye movement sleep has been correlated with memory formation in animals (Smith 1985) and man ( K oella 1985; De Koninck et al 1989;
Smith et al1991). In subjects with mental retardation, the most signilicant electrophysiologic index of cogni tive competence was REM density ( F einberg et al. 1969) .
It is therefore possible that the increase in REM density might reflect not only a sign of central activity, but also a specifIc change in the activity of structures involved in the consolidation of memories.
In conclusion, SDZ ENA 713 is centrally active at well-tolerated doses in man, with a threshold dose of 1 mg, as evidenced by an increase in the density of REM sleep.
